Table 4.

Characteristics for exposures associated with the lowest^a and highest observed mortality among patients treated with systemic anticancer therapy within 3 months of COVID-19 diagnosis

	Lowest observed mortality			Highest observed mortality
	AC-T-likeb	Dara-IMiD-Dex	OFS + AI	Platinum + Etoposide	R-CHOP-likec	DNMTi
	(n = 17)	(n = 10)	(n = 12)	(n = 10)	(n = 22)	(n = 12)
All-cause mortality
30-day mortality	0 (0)	0 (0)	0 (0)	3 (30)	8 (36)	6 (50)
Any mortality	0 (0)	1 (10)	0 (0)	4 (40)	10 (45)	6 (50)
Most common primary cancer	Breast 17 (100)	MM 10 (100)	Breast 11 (92)	SCLC 5 (50)	DLBCL 17 (77)	MDS 7 (58)
Median (IQR) age, years	55 (49-62)	69 (64-80.5)	43.5 (41-46.5)	66.5 (60-74.5)	67.5 (45-79)	67.5 (59-87)
ECOG PS 0-1	16 (94)	5 (50)	11 (92)	6 (60)	18 (82)	7 (58)
Curative treatment intent	17 (100)	0 (0)d	10 (83)	2 (20)	18 (82)	1 (8)

Data presented as n (%) unless otherwise indicated.

AI, aromatase inhibitor; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; COVID-19, coronavirus disease 2019; Dara, daratumumab; DLBCL, diffuse large B-cell lymphoma; DNMTi, DNA methyltransferase inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; IMiD, immunomodulatory imide drugs; IQR, interquartile range; MDS, myelodysplastic syndrome; MM, multiple myeloma; OFS, ovarian function suppression; PS, performance status; SCLC, small-cell lung cancer.

^aNot shown: somatostatin analogs, and CDK4/6i + fulvestrant.

^bCombination of anthracycline, cyclophosphamide, and taxane.

^cCombination of CD20 antibody, cyclophosphamide, anthracycline, vinca alkaloid, and corticosteroid.

^dAll treatment for multiple myeloma except allogeneic stem cell transplant was considered palliative by definition.